Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-associated lymphomas.

D J Straus1

  • 1Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 406, New York, NY 10021, USA. strausd@mskcc.org

Current Oncology Reports
|April 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Chemotherapy only for localized Hodgkin lymphoma.

Journal of internal medicine·2011
Same author

Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

Comparison of survival in cerebral palsy between countries.

Developmental medicine and child neurology·2001
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Intermediate and high-grade non-Hodgkin lymphomas (NHL) are AIDS-defining illnesses, with significantly increased incidence in HIV-infected individuals. These lymphomas often present unusually and may be treatable with intensive therapy due to advancements in antiretroviral therapy.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Hematology

Background:

  • Intermediate and high-grade non-Hodgkin lymphomas (NHL) with a B-cell phenotype are recognized as AIDS-defining illnesses.
  • Individuals with HIV infection exhibit a markedly increased incidence of various lymphomas, including systemic NHL (over 100x), primary CNS NHL (over 3000x), and Hodgkin's disease (approx. 10x).

Purpose of the Study:

  • To summarize the epidemiological and clinical characteristics of non-Hodgkin lymphomas and Hodgkin's disease in the context of HIV infection.
  • To highlight the impact of highly active antiretroviral therapy (HAART) on potential treatment strategies for these malignancies.

Main Methods:

  • Review of existing literature and epidemiological data concerning lymphoma incidence in HIV-infected populations.
  • Analysis of clinical presentations, including extranodal and high-grade histologies, in HIV-associated lymphomas.

Related Experiment Videos

Main Results:

  • HIV-infected individuals show substantially elevated risks for systemic NHL, primary CNS NHL, and Hodgkin's disease.
  • Extranodal involvement and high-grade histologies are frequent findings in HIV-associated lymphomas.
  • The advent of HAART may enable patients to undergo more aggressive treatment regimens.

Conclusions:

  • Non-Hodgkin lymphomas and Hodgkin's disease represent significant oncological challenges in the HIV-infected population.
  • Understanding these associations is crucial for timely diagnosis and management.
  • Evolving treatment paradigms, influenced by HAART, offer potential for improved outcomes.